Isotechnika invited to present at Canaccord Adams Global Growth Conference



    EDMONTON, Aug. 7 /CNW/ - Isotechnika Inc. announced today that Dr.
Randall Yatscoff, Isotechnika's President & Chief Executive Officer, will make
a corporate presentation at the 27th Annual Canaccord Adams Global Growth
Conference. The conference will take place August 7-9, 2007 at the
InterContinental Hotel in Boston. Dr. Yatscoff's presentation is scheduled for
Wednesday, August 8th at 11:30 a.m. ET/9:30 a.m. MT.
    All interested parties are encouraged to view Dr. Yatscoff's presentation
through the Investor Relations section of the corporate website at
www.isotechnika.com.

    Edmonton-based Isotechnika Inc. is an international biopharmaceutical
company focused on the discovery and development of novel immunosuppressive
therapeutics that are designed to offer advantages over other currently
available treatments while offering therapeutic choices to clinicians.
Isotechnika looks to become the market leader of drug therapies for
indications such as transplantation of solid organs (with Hoffman La Roche)
and treatment of autoimmune disorders such as uveitis (with Lux Biosciences)
and psoriasis.
    Isotechnika's lead drug, ISA247, has successfully completed a Phase 3
Canadian trial for the treatment of moderate to severe psoriasis. ISA247 is
currently being investigated in a Phase 3 European/Canadian psoriasis trial
and a Phase 2b North American trial for the prevention of kidney graft
rejection subsequent to transplantation.
    Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol "ISA". More information on Isotechnika can be found
at www.isotechnika.com.

    Forward-Looking Statements
    --------------------------
    This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the potential of its
products, the Company's expectations regarding the issuance of additional
patents and the Company's ability to protect its intellectual property,
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the forward
looking statements. Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and development
projects, the ability to economically manufacture its products, the potential
of its products, the success and timely completion of clinical studies and
trials, the Company's ability to successfully commercialize its products, the
ability of the Company to defend its patents from infringement by third
parties, and the risk that the Company's patents may be subsequently shown to
be invalid or infringe the patents of others. Investors should consult the
Company's quarterly and annual filings with the Canadian commissions for
additional information on risks and uncertainties relating to the forward-
looking statements. Investors are cautioned against placing undue reliance on
forward-looking statements.

    %SEDAR: 00010508E




For further information:

For further information: Stephanie Gillis-Paulgaard, Director, Corporate
Communications, Isotechnika Inc., (780) 487-1600 (243), (780) 484-4105 (fax),
sgillis-paulgaard@isotechnika.com

Organization Profile

ISOTECHNIKA PHARMA INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890